Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13.

PMID:
30104766
2.

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.

J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5.

3.

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.

4.

Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry.

Rennert RC, Khan U, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan A, Leuthardt E, Chen CC.

World Neurosurg. 2018 Aug;116:e566-e570. doi: 10.1016/j.wneu.2018.05.039. Epub 2018 May 14.

5.

T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE.

Clin Cancer Res. 2018 Aug 15;24(16):3792-3802. doi: 10.1158/1078-0432.CCR-18-0047. Epub 2018 Mar 28. Review.

PMID:
29593027
6.

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE.

Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.

PMID:
29437767
7.

Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma.

Woroniecka K, Chongsathidkiet P, Elsamadicy A, Farber H, Cui X, Fecci PE.

Methods Mol Biol. 2018;1741:221-226. doi: 10.1007/978-1-4939-7659-1_18.

PMID:
29392704
8.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

PMID:
29093005
9.

Leptomeningeal disease: current diagnostic and therapeutic strategies.

Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, Lad SP, Fecci PE.

Oncotarget. 2017 Aug 16;8(42):73312-73328. doi: 10.18632/oncotarget.20272. eCollection 2017 Sep 22. Review.

10.

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ.

Neuro Oncol. 2017 Oct 1;19(10):1391-1397. doi: 10.1093/neuonc/nox090.

PMID:
28472527
11.

Prospect of rindopepimut in the treatment of glioblastoma.

Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH.

Expert Opin Biol Ther. 2017 Apr;17(4):507-513. doi: 10.1080/14712598.2017.1299705. Epub 2017 Mar 5. Review.

12.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

13.

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.

Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF.

Oncotarget. 2016 Nov 22;7(47):76565-76576. doi: 10.18632/oncotarget.12088.

14.

Embracing rejection: Immunologic trends in brain metastasis.

Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AK, Vlahovic G, Blackwell KL, Kirkpatrick JP, Fecci PE.

Oncoimmunology. 2016 Apr 11;5(7):e1172153. doi: 10.1080/2162402X.2016.1172153. eCollection 2016 Jul. Review.

15.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS.

Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.

16.

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK.

Cancer Res. 2016 Mar 1;76(5):999-1008. doi: 10.1158/0008-5472.CAN-15-1439. Epub 2016 Feb 1.

17.

Are BiTEs the "missing link" in cancer therapy?

Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH.

Oncoimmunology. 2015 Apr 30;4(6):e1008339. eCollection 2015 Jun. Review.

18.

Editorial: Not everything that matters can be measured and not everything that can be measured matters.

Choi BD, Fecci PE, Sampson JH.

J Neurosurg. 2015 Sep;123(3):543-4. doi: 10.3171/2015.2.JNS142977. Epub 2015 Jun 26. No abstract available.

PMID:
26115465
19.

Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.

Vlahovic G, Fecci PE, Reardon D, Sampson JH.

Neuro Oncol. 2015 Aug;17(8):1043-5. doi: 10.1093/neuonc/nov071. Epub 2015 May 10. No abstract available.

20.

Editorial: Turning fluorescence into black and white.

Fecci PE, Babu R, Adamson DC, Sampson JH.

J Neurosurg. 2015 Jun;122(6):1356-8. doi: 10.3171/2014.10.JNS141788. Epub 2015 Apr 3. No abstract available.

PMID:
25839932
21.

Immunotherapy for malignant glioma.

Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH.

Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S68-77. doi: 10.4103/2152-7806.151341. eCollection 2015.

22.

Peptide vaccines for the treatment of glioblastoma.

Swartz AM, Batich KA, Fecci PE, Sampson JH.

J Neurooncol. 2015 Jul;123(3):433-40. doi: 10.1007/s11060-014-1676-y. Epub 2014 Dec 10. Review.

PMID:
25491947
23.

Immunotherapy for primary brain tumors: no longer a matter of privilege.

Fecci PE, Heimberger AB, Sampson JH.

Clin Cancer Res. 2014 Nov 15;20(22):5620-9. doi: 10.1158/1078-0432.CCR-14-0832. Review.

24.

Antibody-based immunotherapy for malignant glioma.

Gedeon PC, Riccione KA, Fecci PE, Sampson JH.

Semin Oncol. 2014 Aug;41(4):496-510. doi: 10.1053/j.seminoncol.2014.06.004. Epub 2014 Jun 12. Review.

25.

Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage.

Yanamadala V, Walcott BP, Fecci PE, Rozman P, Kumar JI, Nahed BV, Swearingen B.

J Clin Neurosci. 2014 Nov;21(11):1881-4. doi: 10.1016/j.jocn.2014.05.001. Epub 2014 Jun 18.

26.

Immunovirotherapy for the treatment of glioblastoma.

Cheema TA, Fecci PE, Ning J, Rabkin SD.

Oncoimmunology. 2014 Jan 1;3(1):e27218.

27.

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK.

Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27.

28.

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11. doi: 10.1073/pnas.1307935110. Epub 2013 Jun 10.

29.

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT Jr, Mitchell DA, Fecci PE, Sampson JH, Dranoff G.

Expert Rev Vaccines. 2013 Jun;12(6):597-615. doi: 10.1586/erv.13.41. Review.

30.

Regulatory T cells move in when gliomas say "I Do".

Choi BD, Fecci PE, Sampson JH.

Clin Cancer Res. 2012 Nov 15;18(22):6086-8. doi: 10.1158/1078-0432.CCR-12-2801. Epub 2012 Oct 10.

31.

Cancer immunoediting in malignant glioma.

Dunn GP, Fecci PE, Curry WT.

Neurosurgery. 2012 Aug;71(2):201-22; discussion 222-3. doi: 10.1227/NEU.0b013e31824f840d. Review.

PMID:
22353795
32.

Licorice-associated reversible cerebral vasoconstriction with PRES.

Chatterjee N, Domoto-Reilly K, Fecci PE, Schwamm LH, Singhal AB.

Neurology. 2010 Nov 23;75(21):1939-41. doi: 10.1212/WNL.0b013e3181feb299. No abstract available.

33.

Immunotherapy of malignant brain tumors.

Mitchell DA, Fecci PE, Sampson JH.

Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x. Review.

34.

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH.

Clin Cancer Res. 2007 Apr 1;13(7):2158-67.

35.

Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.

Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH.

Clin Cancer Res. 2006 Dec 15;12(24):7306-15.

36.

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305.

37.

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH.

Cancer Res. 2006 Mar 15;66(6):3294-302.

38.

Adoptive immunotherapy for malignant glioma.

Mitchell DA, Fecci PE, Sampson JH.

Cancer J. 2003 May-Jun;9(3):157-66. Review.

PMID:
12952301
39.

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH.

J Neurooncol. 2003 Aug-Sep;64(1-2):161-76. Review.

PMID:
12952297
40.
41.

Clinical immunotherapy for brain tumors.

Fecci PE, Sampson JH.

Neuroimaging Clin N Am. 2002 Nov;12(4):641-64. Review.

PMID:
12687917
42.

Viruses in the treatment of brain tumors.

Fecci PE, Gromeier M, Sampson JH.

Neuroimaging Clin N Am. 2002 Nov;12(4):553-70. Review.

PMID:
12687911

Supplemental Content

Loading ...
Support Center